Skip to content
Open access

COVID-19 Vaccination and Risk of Post-COVID-19 Cardiovascular Disease: A Population-Based Cohort and Target Trial Emulation Study.

Aug 2026 · European Heart Journal - Quality of Care and Clinical Outcomes · 0 citations
Medicine

TL;DR

Findings support COVID-19 vaccination as an important component of strategies to reduce the burden of post-COVID-19 CVD while highlighting the need for further studies to clarify the mechanisms underlying these associations.

Abstract

Background

Whether COVID-19 vaccination is associated with lower long-term cardiovascular risk after SARS-CoV-2 infection and how much infection prevention mediates this association remain unclear.

Objective

To evaluate associations of vaccination, including its timing relative to SARS-CoV-2 infection, with post-COVID-19 cardiovascular disease (CVD), and quantify the contribution of infection prevention.

Methods

This statewide population-based cohort study used linked administrative health data for 2,391,456 adults in Victoria, Australia (2019-2025). Associations of pre- or post-infection vaccination with major adverse cardiovascular events (MACE; primary outcome), stroke, heart failure, acute myocardial infarction (AMI), acute coronary syndrome (ACS), atrial fibrillation (AF), and venous thromboembolism (VTE) were evaluated using time-varying Cox proportional hazards regression, causal mediation analysis, and target trial emulation.

Results

Vaccination was associated with lower hazards of MACE and all secondary outcomes. Estimated absolute risk reductions for MACE were 0.21% with pre-infection vaccination and 0.24% with post-infection vaccination. Three or more vaccine doses were associated with progressively lower hazards across cardiovascular outcomes. Mediation analysis suggested that approximately 68% of the estimated association between vaccination and lower post-COVID cardiovascular risk was not explained by prevention of SARS-CoV-2 infection.

Conclusion

Vaccination before or after SARS-CoV-2 infection was associated with lower hazards of post-COVID-19 cardiovascular outcomes, with stronger observed associations at higher dose numbers. Most of the estimated association was not explained by infection prevention alone. These findings support COVID-19 vaccination as an important component of strategies to reduce the burden of post-COVID-19 CVD while highlighting the need for further studies to clarify the mechanisms underlying these associations.

Read PDF

Similar papers

Open access Aug 2026

Elevated risk of first-time pulmonary hypertension among COVID-19 survivors: a 4.5-year longitudinal study

SARS-CoV-2 infection is independently associated with elevated long-term risk of new-onset PH, whereas only hospitalised COVID-19 status is associated with higher risk of downstream PH-related complications, which underscores the importance of ongoing PH surveillance in COVID-19 survivors.

Sagar Changela, R. Hadidchi, Japji Madan et al. · 0 citations
Open access Aug 2026

Cardiac outcomes following SARS-CoV-2 infection versus BNT162b2 vaccination in adolescents and young adults: a cohort study of 4 million individuals.

BACKGROUND Concerns about myocarditis and mortality after COVID-19 vaccination in pediatrics persist despite limited direct comparisons with SARS-CoV-2 infection risks. We compared risks of myocarditis, pericarditis, and mortality between infection and BNT162b2 vaccination in adolescents and young adults. METHODS Thi...

Eman A. Toraih, Mohammad H. Hussein, S. J. Thomas et al. · 1 citation
Open access Sep 2026

SARS-CoV-2 infection and two-year longitudinal clinical trajectory in pulmonary hypertension: a single-center retrospective exploratory cohort study

Introduction SARS-CoV-2 may promote endothelial injury, pulmonary vascular inflammation, and thrombosis, mechanisms relevant to pulmonary hypertension (PH), but longitudinal post-COVID-19 trajectories in established PH remain poorly defined. Methods We retrospectively analysed 40 PH patients in the prospectively establ...

A. Al-Qahtani, F. Alzubi, D. Obeid et al. · 0 citations
Review Open access Aug 2026

Risk of Post-acute Symptoms and Conditions After SARS-CoV-2 Compared to Other Respiratory Viral Infections: A Systematic Review and Meta-Analysis.

The concept of PCC is supported as one example within the broader spectrum of PAIS, underscoring the need to recognize these conditions after non-COVID respiratory viral infections and to further investigate shared and pathogen-specific mechanisms.

T. Pinto, Andrea Santoro, A. L. D. de Oliveira et al. · 0 citations
Review Open access Sep 2026

Characteristics Associated With Persistent Long COVID Symptoms in Healthcare Personnel Infected With SARS-CoV-2 Between August 2022 and May 2024: A Multicenter Cohort Analysis of US Healthcare Personnel.

Findings underscore the frequency of persistent Long COVID symptoms among HCP and their potential to strain the healthcare workforce.

E. Kontowicz, A. Irish, Lilly C. Lee et al. · 0 citations
Open access Sep 2026

Increasing burden of multiple long-term conditions and mortality risk following COVID-19 diagnosis: a national cohort study of one million adults with cardiovascular disease in England.

MLTCs burden was a stronger determinant of mortality risk than CVD subtype alone, andFindings support moving beyond single-disease models towards integrated, MLTC-informed care, and pandemic preparedness.

Yogini V. Chudasama, S. Shabnam, K. Khunti et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.